A5068086674- Colorectal Cancer Screening and Detection
- COVID-19 and healthcare impacts
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Microscopic Colitis
- Traumatic Brain Injury Research
- Radiomics and Machine Learning in Medical Imaging
- Diagnosis and treatment of tuberculosis
- Health Systems, Economic Evaluations, Quality of Life
- Helicobacter pylori-related gastroenterology studies
- Pancreatic and Hepatic Oncology Research
- Reproductive tract infections research
- Advances in Oncology and Radiotherapy
- COVID-19 Pandemic Impacts
- HIV/AIDS Research and Interventions
- Colorectal and Anal Carcinomas
- Diverticular Disease and Complications
- Advanced Radiotherapy Techniques
- Adolescent Sexual and Reproductive Health
Amsterdam University Medical Centers
2021-2025
Vrije Universiteit Amsterdam
2023-2025
University of Zurich
2023
Public Health Service of Amsterdam
2021-2023
Ludwig-Maximilians-Universität München
2023
University of Amsterdam
2023
University Medical Center Utrecht
2023
Amsterdam UMC Location Vrije Universiteit Amsterdam
2022
National Institute for Public Health and the Environment
2021
Colorectal cancer screening programmes worldwide have been disrupted during the COVID-19 pandemic. We aimed to estimate impact of hypothetical disruptions organised faecal immunochemical test-based colorectal on short-term and long-term incidence mortality in three countries using microsimulation modelling.In this modelling study, we used four country-specific models-Policy1-Bowel (Australia), OncoSim (Canada), ASCCA MISCAN-Colon (the Netherlands)-to potential COVID-19-related Australia,...
Screening for colorectal cancer (CRC) decreases burden through removal of precancerous lesions and early detection cancer. The COVID-19 pandemic has disrupted organised CRC screening programs worldwide, with some completely suspending others experiencing significant in participation diagnostic follow-up. This study estimated the global impact disruptions on outcomes, potential effects catch-up screening.Organised were identified 29 countries, data rates COVID-related changes to 2020...
The fecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening, yet it leaves room for improvement.To develop a multitarget FIT (mtFIT) with better diagnostic performance than FIT.Diagnostic accuracy study.Colonoscopy-controlled series.Persons (n = 1284) from screening 1038) and referral 246) population were classified by their most advanced lesion (CRC [n 47], adenoma 135], serrated polyp 30], nonadvanced 250], 53]), along control participants 769).Antibody-based assays...
Objectives Pre-exposure prophylaxis (PrEP) users are routinely tested four times a year (3 monthly) for asymptomatic Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections on three anatomical locations. Given the high costs of this testing to PrEP programme, we assessed impact 3 monthly screening(current practice), compared with 6 disease burden. We quantified difference in these two frequencies prevalence CT NG among all men who have sex (MSM) at risk an STI, explored...
Objectives Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies clear backlog using limited resources. Methods A range were simulated four country-specific CRC natural-history models: Adenoma and Serrated pathway CAncer (ASCCA)...
The authors assessed whether familial colorectal cancer (FCRC) surveillance in individuals without hereditary CRC can be optimized METHODS: Adenoma and Serrated Pathway to Colorectal Cancer (ASCCA)-FCRC model simulates development with a family history of at 2-fold 4-fold increased risk compared the general population. simulated strategy surveillance, current Dutch guideline (5-yearly colonoscopy between ages 45 75 years), following 3 sets alternative strategies: combining fecal...
Abstract Background Many screening programs for colorectal cancer (CRC) use the fecal immunochemical test (FIT) to triage individuals colonoscopy. Although these reduce CRC incidence and CRC-related mortality, detection of advanced precursor lesions (advanced adenomas serrated polyps) by FIT could be improved. As an alternative FIT, antibody-based multitargetFIT (mtFIT) has been proposed. The mtFIT measures three protein markers: hemoglobin, calprotectin, serpin family F member 2. In a...
OBJECTIVES To facilitate informed decision making on participating in colorectal cancer (CRC) screening, we assessed the benefit-harm balance of CRC screening for a wide range subgroups over different time horizons.METHODS The study combined incidence proportions benefits and harms (not) estimated by Adenoma Serrated pathway to CAncer microsimulation model, preference eliciting survey, modeling combining all outcomes determine net health benefit 10, 20, 30 years.Probability was 210 based...
Aims The yield of colonoscopy surveillance after colorectal cancer screening is limited. To lower patient burden and healthcare costs, there a need to reduce colonoscopies in which no advanced neoplasia detected. MOlecular stool testing for Colorectal CAncer Surveillance (MOCCAS) study evaluated whether stool-based could safely the number colonoscopies.
Aims Colorectal cancer (CRC) screening programs worldwide have been disrupted during the COVID-19 pandemic. This study aimed to estimate impact of hypothetical disruptions organized FIT-based CRC on short- and long-term incidence mortality in three countries using microsimulation modelling.
Aims The fecal immunochemical test (FIT) is widely used in colorectal cancer (CRC) screening. However, FIT leaves room for improvement, particular detecting advanced adenomas. To this end the present study aims to design a multi target (mtFIT) improve FIT-based